Preston Wendell Wells Sells 165 Shares of Stryker (NYSE:SYK) Stock

Stryker Corporation (NYSE:SYK) CFO Preston Wendell Wells sold 165 shares of the company’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $365.88, for a total transaction of $60,370.20. Following the sale, the chief financial officer directly owned 6,694 shares of the company’s stock, valued at $2,449,200.72. This represents a 2.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Stryker Price Performance

NYSE:SYK traded down $3.77 during mid-day trading on Thursday, reaching $360.46. The stock had a trading volume of 1,381,441 shares, compared to its average volume of 1,448,508. The stock has a 50-day simple moving average of $370.25 and a two-hundred day simple moving average of $380.91. The stock has a market capitalization of $137.85 billion, a PE ratio of 47.74, a P/E/G ratio of 2.66 and a beta of 0.94. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. The company had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.Stryker’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, equities analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a report on Saturday, October 18th. Redburn Partners set a $420.00 target price on shares of Stryker in a research note on Thursday, September 18th. Rothschild & Co Redburn assumed coverage on shares of Stryker in a report on Thursday, September 18th. They set a “neutral” rating and a $420.00 price target for the company. Evercore ISI cut their price objective on Stryker from $410.00 to $405.00 and set an “outperform” rating on the stock in a report on Friday, October 31st. Finally, UBS Group set a $408.00 price objective on Stryker in a research report on Monday, October 13th. Thirteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and a consensus price target of $434.37.

Institutional Trading of Stryker

A number of institutional investors and hedge funds have recently bought and sold shares of SYK. Vanguard Group Inc. lifted its holdings in Stryker by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 33,773,399 shares of the medical technology company’s stock worth $12,485,012,000 after buying an additional 272,828 shares during the period. State Street Corp lifted its stake in shares of Stryker by 1.0% in the second quarter. State Street Corp now owns 14,956,732 shares of the medical technology company’s stock worth $5,929,765,000 after acquiring an additional 150,204 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Stryker by 9.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock valued at $4,515,847,000 after acquiring an additional 1,021,496 shares during the last quarter. Geode Capital Management LLC increased its position in Stryker by 1.1% during the 2nd quarter. Geode Capital Management LLC now owns 7,393,611 shares of the medical technology company’s stock valued at $2,910,445,000 after purchasing an additional 79,654 shares during the period. Finally, Alliancebernstein L.P. raised its holdings in Stryker by 13.3% during the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after purchasing an additional 741,542 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.